The complete analytical guide for pharma IP teams, portfolio managers, and generic entrants: from claim construction and Markush deconstruction to […]
How Chemical Patent Non-Infringement Strategy Wins Drug Markets Read Post »
1. The Approval Data That Rewrites the Narrative The dominant story in pharma investment circles for the better part of
By the time a blockbuster drug’s first Paragraph IV challenger is ready to launch, the brand manufacturer has often already
The Authorized Generic Gambit: How Brand Pharma Weaponizes Its Own Patent Expiry Read Post »
Argentina’s pharmaceutical market is a $7.3 billion commercial arena projected to reach $14.2 billion by 2030 — and it is
The three most consequential generic drug launches in pharmaceutical history share almost nothing in surface mechanics. One ended in a
The $400B Generic Drug Playbook: How Lipitor, Plavix, and Gleevec Were Won Read Post »
The global generic drug industry saves the U.S. healthcare system roughly $2.9 trillion per decade. In high-income markets, this model
Generic Drugs for Low-Income Markets: The Formulation, IP, and Regulatory Playbook Read Post »
Biologic drugs generate more revenue per product than any other class of medicine. They also carry more patents, attract more
The Hatch-Waxman Act created the modern generic drug industry in 1984. Forty years later, the Paragraph IV certification it established
How Paragraph IV Patent Challenges Actually Work: The $200B Generic Drug Playbook Read Post »
The Patent Trial and Appeal Board has quietly become the most consequential forum in pharmaceutical IP. This is the definitive
Drug Patents vs. PTAB:Who Actually Wins? Read Post »
Sign in or create a free account to read this DrugPatentWatch article
